Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
LTG-305 Report
Name: LTG-305 Name (English): LTG-305
Originator: Latigo Biotherapeutics Class: Non-opioid analgesics; Small molecules Mechanism of Action: Nav1.8 voltage-gated sodium channel inhibitor Indication: Chronic pain (investigational) Highest Development Phase: Phase I
Clinical Trials:
- NCT06554574: A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants. This study is evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of oral LTG-305 in healthy volunteers. It includes single-ascending dose (SAD) and multiple-ascending dose (MAD) cohorts, as well as an evaluation of pain tolerance using a cold pressor test in male participants. The trial began in October 2024, with topline results expected by mid-2025.
Recent Events:
- October 2024: First participant dosed in the Phase 1 clinical trial.
- August 2024: Preclinical trials in Pain in USA (PO) prior to August 2024.
- August 2024: Latigo Biotherapeutics plans a phase I safety and pharmacokinetics trial in healthy subjects in New Zealand (PO) (NCT06554574).
- March 2025: Latigo Biotherapeutics raised $150 million in a Series B funding round to advance the development of LTG-305 and other non-opioid pain management drugs.
Target: Nav1.8 voltage-gated sodium channel, which is crucial for the transmission of pain signals. By selectively inhibiting Nav1.8, LTG-305 aims to provide effective pain relief with minimal central nervous system side effects.
Rationale: There is a significant unmet need for non-opioid pain treatments due to the limitations and risks associated with current therapies, including opioids (addiction, dizziness, drowsiness). LTG-305 represents a novel small molecule approach that targets the underlying mechanisms of chronic pain at its source.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/08/15 | Phase 1 | Completed | Latigo Biotherapeutics |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.